Abstract. The aim of the present study was to develop a new therapeutic drug to improve the prognosis of ovarian cancer patients. Human urokinase-type plasminogen activator (uPA) 17-34 -kunitz-type protease inhibitor (KPI) eukaryotic expression vector was constructed and recombinant human uPA 17-34 -KPI (rhuPA 17-34 -KPI) in P. pastoris was expressed. In the present study, the DNA sequences that encode uPA 17-34 amino acids were created according to the native amino acids sequence and inserted into the KPI-pPICZαC vector, which was constructed. Then, uPA 17-34 -KPI-pPICZαC was transformed into P. pastoris X-33, and rhuPA 17-34 -KPI was expressed by induction of methanol. The bioactivities of a recombinant fusion protein were detected with trypsin inhibition analysis, and the inhibitory effects on the growth of ovarian cancer cells were identified using the TUNEL assay, in vitro wound-healing assay and Matrigel model analysis. The results of the DNA sequence analysis of the recombinant vector uPA 17-34 -KPI-pPICZα demonstrated that the DNA-encoding human uPA 17-34 amino acids, 285-288 amino acids of amyloid precursor protein (APP) and 1-57 amino acids of KPI were correctly inserted into the pPICZαC vector. Following induction by methonal, the fusion protein with a molecular weight of 8.8 kDa was observed using SDS-PAGE and western blot analysis. RhuPA 17-34 -KPI was expressed in P. pastoris with a yield of 50 mg/l in a 50-ml tube. The recombinant fusion protein was able to inhibit the activity of trypsin, inhibit growth and induce apoptosis of SKOV3 cells, and inhibit the invasion and metastasis of ovarian cancer cells. By considering uPA 17-34 amino acid specific binding uPAR as the targeted part of fusion protein and utilizing the serine protease inhibitor activity of KPI, it was found that the recombinant fusion protein uPA 17-34 -KPI inhibited the invasion and metastasis of ovarian tumors, and may therefore be regarded as effective in targeted treatment.
Introduction
Ovarian cancer, which is a heterogeneous and rapidly progressive disease of low prevalence, is a gynecological malignant tumor with a high mortality rate (1) . Due to the resistance of chemotherapy and tumor recurrence, the mortality rate among women diagnosed with metastatic diseases caused by ovarian cancer remains high, with only 27% of patients surviving >5 years post-diagnosis (2) . Therefore, the development of new therapeutic drugs is important to improve the prognosis of ovarian cancer patients.
The human urokinase plasminogen activator (uPA) gene is located at the long arm of chromosome 10, is 6.5 kb in length and consists of 11 exons, and can be transcripted into mature mRNA of 2.4 kb in length. The uPA is an extracellular serine protease that binds to its receptor, urokinase plasminogen activator receptor (uPAR and CD87), and converts plasminogen into plasmin at the cell-matrix interface (3, 4) . uPA and uPAR are involved in the control of extracellular matrix turnover, cell migration, invasion and cell signaling leading to a variety of different responses under physiological and pathological conditions (5, 6) . Previous findings indicate that during the period of cancer cell invasion and metastasis, proteolytic enzymes participate in the degradation of extracellular matrix components (7, 8) . The specific uPA/uPAR binding results in the enzymatic activity of uPA being concentrated on the cell surface, not only reinforcing the activation of plasminogen, and consequently accelerating pathological processes such as extracellular stromatin degradation and cellular invasion, but also participating in the generation of new blood vessels closely associated with tumor metastasis (9, 10 uPAR are overexpressed in human ovarian cancer cells (11, 12) , and the binding of uPA with uPAR on the surface of ovarian cancer cell membranes is considered as the key to promoting metastasis of ovarian cancer by uPA (8, 9) . uPA comprises a carboxyl-terminal serine protease domain and an amino-terminal fragment (ATF) that contains all of the determinants required for binding to its receptor. The 17-34 amino acids of ATF consist of an amino acid fragment that is crucial to uPA/uPAR binding (13, 14) . Therefore, we aimed to create a type of fusion protein that contains uPA 17-34 amino acids and activated protein. Through targeted binding between the shortest conjugation fragment of uPA 17-34 amino acids and uPAR on ovarian cancer tissues, the fusion protein we designed was able to enter the targeted cells accurately.
The major isoforms of human amyloid precursor protein (APP), APP695 and APP751, differ due to the presence of a kunitz-type protease inhibitor (KPI) domain in the extracellular region (15) . KPI is a type of stable serine protease inhibitor that inhibits the activity of serine protease and its decomposition on proteins, blocks the invasion and metastasis processes of tumor cells and recovers the cell barrier.
We constructed the pPICZαC-uPA 17-34 -KPI expression vector which contained the nucleotide sequences encoding human uPA 17-34 and 285-345 amino acids of APP, which contained the 57 amino acid KPI domain (residues 289-345) (16) . The P. pastoris expression system was then used to express the secreted recombinant human uPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI (rhuPA 17-34 -KPI) fusion protein. By considering uPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] amino acid specific binding uPAR as the targeted part of fusion protein, and utilizing serine protease inhibitor activity of KPI, the recombinant fusion protein, uPA 17-34 -KPI, was found to inhibit the invasion and metastasis of ovarian tumors and serve as an effective targeted treatment.
Materials and methods
Strains, vectors and reagents. The DNA sequence that encodes human uPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] amino acids was produced by Sangon Biotech Co., Ltd. (Shanghai, China). The P. pastoris X-33, H-DMEM culture medium and zeocin antibiotic were purchased from invitrogen-Life Technologies (Carlsbad, CA, USA). The restrictive enzyme, T4 DNA ligase, Taq DNA polymerase and plasmid preparation kit were purchased from Takara (Biotechnology Co., Ltd., Dalian, China). SP Sepharose XL and Source™ 30 RPC reversed phase hydrophobic chromatography were purchased from Phamarcia (Uppsala, Sweden). yPD, BMgy, and BMMY media were prepared as a formula (Invitrogen-Life Technologies). The SKOV3 human ovarian cancer cell line was kept in the School of Pharmaceutical Sciences of Jilin University, and KPI-pPICZαC was constructed in our laboratory. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI-pPICZαC expression vector. The DNA that encodes uPA 17-34 amino acids was produced according to its native amino acids sequence (Sangon Biotech Co., Ltd). To improve the yield of recombinant protein, synonymous codons were replaced by yeast-biased codons. The DNA sequence used was: 5'-TC gAg AAg AgA ggT ACT TgT GTT TCT AAC AAG TAC TTC TCT AAC ATT CAC TGG TGT AAC TGT CCA GAG GTT GTT AGA GAG GTT TGC A-3'; complementary strand, 5'-AAC CTC TCT AAC AAC CTC TGG ACA GTT ACA CCA GTG AAT GTT AGA GAA gTA CTT gTT AgA AAC ACA AgT ACC TCT CTT C-3'.
Construction of the uPA
Annealing was performed as follows: 6 µl 0.5 mmol NaCl and 25 µmol single-strand DNA were mixed. The compound was then boiled for 3 min at 80˚C and cooled down to room temperature gradually. After being annealed, the complementary strands contained cohesive ends of XhoI and PstI, while the Kex2 site was followed by the XhoI site.
KPI-pPICZαC was constructed and kept in our laboratory. In addition to the 57 amino acids KPI domain, the recombinant plasmid contained DNA that encodes an additional four amino acid residues that correspond to amino acids 285-288 of APP (16) . The DNA sequence of 61 amino acids was inserted into pPICZαC between XhoI and XbaI. The KPI-pPICZαC plasmid was digested with XhoI and PstI and then the DNA sequence that encodes uPA 17-34 amino acids was inserted into the corresponding sites to construct the uPA 17-34 -KPIpPICZαC expression plasmid.
The recombinant plasmid was transformed into competent cells of Escherichia coli XL-Blue, and the recombinant colonies were selected by zeocin (25 µg/ml) resistance. The positive clones were incubated in LB liquid medium for 12 h and the plasmids were extracted using a plasmid preparation kit. The nucleotide sequences of the inserted DNA and flanking sequence were verified by sequencing with the genome Lab DTCS-quick Start kit and CEq 2000 DNA analysis system (Beckman Coulter inc., Brea, CA, USA).
Transformation and induced expression of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. The recombinant plasmid with correct sequence was linearized with SacI and introduced into the competent cells of the P. pastoris X-33 strain by electroporation using a micropulser (Bio-Rad, hercules, CA, USA) according to the pPiCZα vector manual. After electroporation, the mixture was spread on a YPD culture plate containing zeocin (100 mg/l) and cultured at 30˚C for 3 days. The blank plasmid of pPiCZαC was also transformed as a negative control.
After the transformants with zeocin resistance became visible, some monoclonal transformants were randomly selected and cultured in 10 ml BMgy culture medium at 30˚C with agitation at 225 rpm for 24 h. The culture media (0.5 ml) were sampled, and centrifuged at 10,000 rpm for 5 min at 4˚C and the cell pellets were used for genomic DNA analysis. The yeast genomic DNA was extracted using the boiling-freezingboiling method and PCR identification was carried out to select the P. pastoris X-33 strain which was successfully. transformed into recombinant plasmid
The remaining culture medium was centrifuged and cell pellets were resuspended in 10 ml BMMY medium to induce expression for 7 days. The culture medium (0.5 ml) was sampled daily and centrifuged at 10,000 rpm for 5 min at 4˚C. The supernatant was used for recombinant protein detection. Methanol was added every 24 h to a final concentration of 0.5% (v/v) to induce the expression of the target protein. SDS-PAGE and trypsin inhibition analyses were performed to select high-level expression clone cells.
Optimized expression of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI in P. pastoris. To ascertain the optimized pH value and induction time in order to achieve a high-level expression of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI, a high-level expression cell colony was cultured with different pH values (3.5-7.5 with 0.5 intervals) using culture medium. The procedure followed was the same as mentioned above, and the pH values were adjusted daily with disodium hydrogen phosphate and citric acid. At the desired time points, 0.5 ml cell aliquots were removed and replaced with equal amounts of fresh medium. The supernatant samples were used for trypsin inhibition analysis. To optimize the induction time, the supernatant samples from 0 to 7 days under the same pH value were detected by trypsin inhibition analysis. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. SDS-PAGE analysis was performed using 18% separation gel. For western blot analysis, proteins in the gel were transferred to a nitrocellulose membrane. The membrane was blocked with 5% BSA for 1 h and then incubated with the murine anti-human urokinase monoclonal antibody (American Diagnostica inc., Stamford, CA, USA) for 12 h. After being washed, the membrane was incubated with the goat antimouse HRP-conjugated IgG (Dingguo, China), diluted to 1:250. The bound antibody was detected using 3,3'-diaminobenzidine (DAB).
SDS-PAGE and western blot analyses of rhuPA
Trypsin inhibition activity analysis of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. The trypsin inhibition experiment was used to determine the activity and quantity of rhuPA 17-34 -KPI. As shown in Table I , 650 µl Tris-HCl (50 mmol/l, pH 8.0) buffer, 60 µl culture supernatant and 25 µl trypsin (20 U/ml) were mixed in 1.5-ml tubes and incubated at 37˚C for 20 min. Then, 10 µl N-benzoyl-DL-arginine-4-nitroanilide hydrochloride (DL-BAPNA; 200 mM/l) was added. After being incubated at 37˚C for 10 min, the reaction was stopped by adding 450 µl 30% (v/v) acetic acid. The absorbance of each tube was measured at 410 nm. Each sample was measured three times and the mean value was used for analysis. The percentage of trypsin inhibition activity (TIA) was calculated based on the formula:
A1 -Ao where A 0 , A 1 , A 410 were tube 0 and 1; and As, A 410 the sample tube (tube S).
Purification of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. After being induced by methanol for 5 days, the supernatant of the fermentation broth was collected by centrifugation. After being diluted four times with 20 mM NaAc-HAc (pH 3.0) buffer, the pH of the supematant was adjusted to 3.0 with 1 M acetate acid. The supernatant was loaded onto the cation exchange chromatography (SP Sepharose XL) which was equilibrated with 20 mM NaAc-HAc (pH 3.0) buffer. The column was washed extensively with the same buffer. The bound protein was eluted with a linear gradient of NaCl (0.1-1.0 M) and protein elution was monitored by measuring the absorbance at 280 nm and identified by trypsin inhibition analysis. The column effluent containing rhuPA 17-34 -KPI was loaded onto a reverse phase column (Source 30) which was equilibrated with 0.1% trifluoro acetic acid (TFA) for further purification. RhuPA 17-34 -KPI was eluted using 50% methanol containing 0.1% TFA and was concentrated by vacuum distillation and freeze drying to remove the methanol.
N-terminal amino acid sequence analysis.
To determine the N-terminal sequence, the purified rhuPA 17-34 -KPI was electrophoresed on 18% SDS-PAGE gel and electroblotted on a PVDF membrane. After being blotted, the PVDF membrane was stained with Coomassie Brilliant Blue R250, and the rhuPA 17-34 -KPI band was extracted and determined by automated Edman degradation performed on a model PPSq-21A protein sequencer (Shimadzu, Japan).
Inhibitory effects of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI on the growth of ovarian cancer cells. The growth and proliferation of SKOV3 ovarian carcinoma cells was observed using a Cell Counting Kit-8 (CCK-8) assay. Briefly, the SKOV3 human ovarian cancer cell line was maintained in H-DMEM with 10% fetal bovine serum (FBS) and 100 U/ml of penicillin/streptomycin, at 37˚C in a humidified atmosphere containing 5% CO 2 . The cells (2x10 4 ) were seeded in 96-well plates containing complete medium and incubated for 24 h followed by different doses of rhuPA 17-34 -KPI. SKOV3 cells were treated with H-DMEM (as control) and 0.075, 0.15, 0.3, 0.6, 1.2 and 2.4 mg/ml rhuPA 17-34 -KPI, respectively, for 48 h. Subsequently, 10 µl of the CCK-8 solution was added to each well and the cells were incubated for 2 h. The absorbance was detected at 450 nm using a microplate reader (Bio-Rad instruments, hercules, CA, USA). The percentage of inhibition rate of rhuPA 17-34 -KPI (I) was calculated using the formula:
Ac where Ac, A 450 was the control group; and As, A 450 the different doses of rhuPA 17-34 -KPI.
TUNEL assay for apoptosis. Apoptosis was determined using a TUNEL assay. SKOV3 cells at a density of 1x10 5 cells/well were seeded in 1.3 mm coverslips in 24-well plates and incubated Ovarian cancer cell invasion assay. The effects of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI on the inhibition of invasion of SKOV3 cells were detected in a two-compartment Boyden chamber (Transwell) as previously described (18) . Briefly, SKOV3 cells were treated with rhuPA 17-34 -KPI at a concentration of 1.2 or 2.4 mg/ ml for 24 h. The cells were collected and resuspended with serum-free H-DMEM. Cells (2x10 4 ) were seeded in the upper compartment, and H-DMEM with 20% FBS was placed in the lower compartment of the Boyden chamber. After incubation at 37˚C for 6 h, the cells on the lower side were fixed, stained and observed. The invasion ability of tumor cells was determined by the mean value of cells migrating through the membrane.
Statistical analysis. Data are presented as means ± SEM. Statistical analyses were performed using the Student's t-test. P<0.05 was considered to indicate a statistically significant result.
Results

Identification of recombinant plasmid uPA 17-34 -KPI-pPICZα.
Since there is a PstI site in the DNA sequence that encodes KPI 6-8 amino acids, we created a DNA sequence that encodes uPA 17-34 amino acids and a few amino acids corresponding to the N-terminal amino acid sequence of KPI. After the uPA sequence was inserted into the KPI-pPICZαC plasmid (digested with XhoI and PstI), the recombinant plasmid uPA 17-34 -KPI-pPICZα was performed using DNA sequence analysis. The results of the DNA sequence analysis of the recombinant expression vector uPA 17-34 -KPI-pPICZα (data not shown) demonstrated that the DNA sequences encoding human uPA 17-34 and 285-288 amino acids of APP, and 1-57 amino acids of KPI were correctly inserted into the pPICZαC vector and the amino acid sequence was identical to that logged in GenBank. The schematic drawing of uPA 17-34 -KPI-pPICZα presents the structure of recombinant plasmid (Fig. 1) .
Screening of positively transformed yeast strain with PCR.
After being cultured at 30˚C for 3 days, a number of transformants with zeocin resistance became visible on the YPD agar plates containing 0.1 g/l zeocin. 5' AOX and 3' AOX were used as primers to perform PCR analysis of genomic DNA. PCR products were used to carry out 1.0% agarose gel electrophoresis analysis. There were ~750 bp amplification bands for the samples that were transformed with uPA 17-34 -KPI-pPICZα, but ~400 bp for the control sample which was transformed with the pPICZαC blank plasmid (Fig. 2) . The results showed that, the DNA sequence encoding the fusion protein was integrated into >90% of clones which were transformed with the recombinant expression vector, uPA 17-34 -KPI-pPICZα.
Expression of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. The positive transformants were induced to express recombinant protein by methanol for 7 days. On the third day after induction with methanol the supernatants were identified using SDS-PAgE analysis and the transformant presenting with the highest expression level of rhuPA 17-34 -KPI was utilized to optimize the expression of the fusion protein in P. pastoris. The results indicated that rhuPA 17-34 -KPI was expressed following the induction of methanol. However, the recombinant protein expression in the transformant-containing blank plasmids of pPICZαC was negative. Based on the amino acids sequence, the calculated molecular weight of rhuPA 17-34 -KPI was 8.8 kDa, which was consistent with the result of the SDS-PAGE measurement (Fig. 3A) .
Identification of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. The primary purified recombinant protein was identified by western blot analysis. The results demonstrated that the recombinant protein bound to the anti-human urokinase monoclonal antibody. No band was observed in lane 2, which was the supernatant of transformant containing blank plasmids of pPICZαC (Fig. 3B) . N-terminal amino acid sequence analysis of the purified recombinant protein offered the first 15 amino acids as G T C V S N K Y F S N I H W C. The N-terminal sequence of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI was identical to that of human uPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , confirming the successful expression and purification of rhuPA 17-34 -KPI.
Optimized expression of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. Trypsin inhibition activity analysis was performed to determine the optimal expression conditions of rhuPA 17-34 -KPI. After a series of experi ments, the optimal expression conditions of rhuPA 17- 34 -KPI were obtained as follows: the optimal pH was 5.5 ( Fig. 4A) , and the optimal induction time-points were identified on the 5th day for the strain (Fig. 4B) at 30˚C, following daily methanol addition at a concentration of 0.5% (v/v). Under these conditions, the yield of rhuPA 17-34 -KPI was 50 mg/l.
Anticancer effects of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. The anticancer activity of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI was detected by its antiproliferation effects on SKOV3 cells. We observed the cell morphology of SKOV3 cells following treatment with rhuPA 17-34 -KPI at different doses. In the control group, the cells grew well with adherence and the cells were fusiform or diamond shaped. However, following treatment with rhuPA 17-34 -KPI, the cells membrane shrinking and cytoplasm spilling were evident. The CCK-8 assay was used to detect the quantity of cells. As a result, rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI treatment resulted in a dose-dependent inhibition of growth on SKOV3 cells at 48 h. The inhibition rate was ~80% at the dose of 2.4 mg/ml (Fig. 5) .
The TUNEL assay demonstrated that ovarian cancer cells underwent apoptosis following treatment with rhuPA 17-34 -KPI. Data from all the designated fields were pooled to obtain the apoptosis index, which is the percentage of TUNELpositive cells in total cells manually counted in six random fields. The apoptotic indices of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI treatment groups were markedly increased compared with the normal control group. As a result, rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI treatment caused a dose-dependent increase apoptosis in SKOV3 cells within 24 h (Fig. 6A) . [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI. An in vitro wound-healing assay was performed to examine whether rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI inhibited the migration of ovarian cancer cells. As shown in Fig. 6B , the cells in the control group that were not treated with rhuPA 17-34 -KPI had migrated into and largely covered the original wound area at 24 h after the scratch. However, the cells treated with rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI at different doses failed to migrate substantially into the wound area.
Inhibition of invasion and metastatic effects of rhuPA
The effects of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI on the invasion of ovarian cancer cells were evaluated using the Matrigel model. RhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI reduced the number of invaded cells in a dose-dependent manner (Fig. 6C) . These findings indicated that rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPi significantly inhibited the invasion and metastasis of SKOV3 cells.
Discussion
Effective anticancer drugs are developed by clinical doctors and investigators with great effort. Surgery, chemotherapy and radiotherapy are conventional treatments used in the clinic. However, for patients considered unsuitable for surgical treatment and who do not tolerate the side effects of chemotherapy and radiotherapy, new therapeutic drugs and measures are of utmost importance. With the rapid development of molecular biology, immunology and genetic engineering technology in recent years, the focus has been on new types of drugs that have potential anticancer effects. The sequence of 17-34 amino acids of uPA is the key to uPA/uPAR binding, which makes the enzymatic activity of uPA concentrated on the cell surface (9, 10) . Therefore, in the present study, by considering uPA 17-34 amino acids specifically binding to uPAR that is overexpressed in human ovarian cancer tissues, we determined whether the fusion protein was able to bind to target cells accurately.
Previous findings have shown that the role of the proteolytic enzyme is indispensable in the invasion and metastasis of tumor cells, and the concentrations of many serine proteases are positively correlated with tumor invasion. KPI, which was selected to utilize anticancer effects, is a type of stable serine protease inhibitor. It inhibits the activity of serine protease and its decomposition on proteins. Therefore, it is possible to block the invasive and metastastic processes of tumor cells and recover the cell barrier (19) .
The present study aimed to construct the fusion protein that can be applied to effective targeted treatment for ovarian cancer. In the present study, uPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI-pPICZαC eukaryotic expression vector was constructed successfully. After being transformed into P. pastoris and induced by methanol, rhuPA 17-34 -KPI was detected using SDS-PAGE and western blot analyses. We established a stable and effective rhuPA17-KPI expression system in P. pastoris. The α-factor signal peptide in the yeast expression vector was effective in guiding the secretion of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI into the culture broth, which facilitates the production of large-scale fermentation for direct industrial application without complicated purification procedures (20) .
Trypsin inhibition analysis showed that rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI presented trypsin inhibition activity similar to the serine protease inhibitor. Moreover, rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI inhibited the proliferation of SKOV3 cells and induced apoptosis of ovarian cancer cells. In vitro wound healing assay and Matrigel model analysis revealed the inhibitory effects of rhuPA [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -KPI on the invasion and metastasis of ovarian cancer cells. Thus, the present study suggests an early-stage experimental basis for the further study of the treatment of ovarian cancer using rhuPA 17-34 -KPI.
